Stockscreener 앱 받기
6.76
1.46%
-0.10
시간 외 거래:
6.87
0.11
+1.63%
Biocryst Pharmaceuticals Inc 주식(BCRX)의 최신 뉴스
Barclays Lowers Price Target on BioCryst Pharma (BCRX) to $9 wit - GuruFocus
BioCryst Pharmaceuticals (NASDAQ:BCRX) Releases Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q3 2025 Earnings Call Transcript - Insider Monkey
Needham's Analyst Update: BioCryst Pharma (BCRX) Price Target Re - GuruFocus
Hussman Strategic Advisors Inc. Has $1.88 Million Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
What technical models suggest about BioCryst Pharmaceuticals Inc.’s comebackQuarterly Profit Review & Stock Portfolio Risk Control - newser.com
BioCryst Pharmaceuticals (BCRX) Is Up After Raising ORLADEYO Outlook and Returning to Profitability – What’s Changed - Yahoo Finance
BioCryst Pharmaceuticals Inc.’s volatility index tracking explained2025 Price Targets & Free Real-Time Volume Trigger Notifications - newser.com
T-cell Lymphoma Market Report with Detailed Study Analysis - openPR.com
BioCryst: Q3 Earnings Snapshot - CT Insider
Is BioCryst Pharmaceuticals Inc. stock ready for a breakoutWeekly Trend Report & High Conviction Buy Zone Picks - newser.com
BioCryst Pharmaceuticals (BCRX): Forecasts Call for 56.3% Annual Earnings Growth Heading Into Earnings Season - Yahoo Finance
BioCryst Pharmaceuticals Inc (BCRX) Q3 2025 Earnings Call Highlights: Strong Orladeo Growth and ... - Yahoo Finance
BioCryst Pharmaceuticals, Inc. Appoints Ron Dullinger as Chief Commercial Officer, Effective January 1, 2026 - MarketScreener
BioCryst Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2025 - MarketScreener
BioCryst Pharmaceuticals Inc reports results for the quarter ended September 30Earnings Summary - TradingView
BioCryst (BCRX) Q3 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: BioCryst Q3 2025 earnings beat estimates, stock dips - Investing.com
BioCryst (BCRX) Revenue Falls Short but Strategic Moves Drive Fu - GuruFocus
BioCryst Pharmaceuticals (BCRX) Reports Strong Q3 Earnings, Rais - GuruFocus
BioCryst Reports Q3 2025 Financial Growth and Strategy - TipRanks
BioCryst Pharmaceuticals Inc (BCRX) Q3 2025 Earnings: EPS of $0. - GuruFocus
BioCryst (BCRX) Adjusts 2025 Financial Projections for ORLADEYO - GuruFocus
Earnings Flash (BCRX) BioCryst Pharmaceuticals, Inc. Reports Q3 Revenue $159.4M, vs. FactSet Est of $163.0M - MarketScreener
Earnings Flash (BCRX) BioCryst Pharmaceuticals, Inc. Posts Q3 Adjusted EPS $0.16 per Share, vs. FactSet Est of $0.07 - MarketScreener
BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update - Bluefield Daily Telegraph
Will BioCryst Pharmaceuticals Inc. stock maintain growth storyQuarterly Growth Report & AI Powered Market Entry Ideas - newser.com
When is the best time to exit BioCryst Pharmaceuticals Inc.July 2025 Short Interest & AI Driven Stock Reports - newser.com
Why BioCryst Pharmaceuticals Inc. stock could benefit from AI revolution2025 Top Decliners & Consistent Return Investment Signals - newser.com
Is BioCryst Pharmaceuticals Inc. stock bottoming out2025 Volatility Report & Technical Entry and Exit Tips - newser.com
Will BioCryst Pharmaceuticals Inc. stock attract ESG investors2025 Technical Patterns & Precise Buy Zone Identification - newser.com
Why retail investors pile into BioCryst Pharmaceuticals Inc. stock2025 Dividend Review & Technical Entry and Exit Alerts - newser.com
Y Intercept Hong Kong Ltd Increases Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat
Promising Biotech Stocks To Follow TodayOctober 14th - MarketBeat
# BioCryst’s SWOT analysis: stock positioned for growth amid HAE market expansion - Investing.com
BioCryst Pharmaceuticals (BCRX) Price Target Increased by 19.59% to 21.51 - Nasdaq
3.60%
0.45%
자본화:
|
볼륨(24시간):